BusinessCURE Pharmaceutical Secures Two Patents for the Extraction and Purification of Bioactive Cannabinoid MoleculesBy Nasdaq OMXApr 4, 2018, 12:57 PM UTC
BusinessCURE Pharmaceutical Reports Strong Progress and Sets Growth Roadmap for Remainder of YearBy Nasdaq OMXApr 3, 2018, 12:57 PM UTC
BusinessBiopharmaceutical Veteran Joins CURE Pharmaceutical to Lead ManufacturingBy Nasdaq OMXMar 14, 2018, 1:01 PM UTC
BusinessCURE Pharmaceutical Adds Healthcare Luminary To Advisory Board, Secures $1 Million Investment as a Bridge to UplistingBy Nasdaq OMXFeb 21, 2018, 11:00 AM UTC
BusinessOak Therapeutics Announces Results of Bioequivalence Study of Company’s Oral Dissolvable Strip for TuberculosisBy Nasdaq OMXOct 3, 2017, 1:00 PM UTC
BusinessCURE Pharmaceutical Subsidiary, Oak Therapeutics, Completes Critical Milestone in Phase 1 of NIH Grant to Develop Oral Dissolvable Strip for TuberculosisBy Nasdaq OMXAug 22, 2017, 3:19 PM UTC
BusinessCURE Pharmaceutical Enters Partnership to Distribute New Erectile Dysfuntion Drug Using Company’s Proprietary CureFilm™ Into Asian MarketBy Nasdaq OMXAug 10, 2017, 1:00 PM UTC
BusinessLeading OTF Manufacturer CURE Pharmaceutical Comments on New Report Showing Exponential Growth in Thin Film Drug Manufacturing MarketBy Nasdaq OMXJun 7, 2017, 3:14 PM UTC
